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A DNA element in the a1 type III collagen promoter mediates [1], where it plays a fundamental homeostatic effect on
a stimulatory response by angiotensin II. the ultrafiltering functions [2]. This is not, however, the
Background. Angiotensin II (Ang II) plays an important unique function of Ang II. The peptide has been recentlyrole in extracellular matrix deposition and tissue scarring in
recognized to have a fine regulatory effect on cell growththe kidney and the heart. The mechanism for extracellular
[3, 4] and synthetic properties mainly related to the pro-matrix stimulation by Ang II is currently hypothetical, with
one possibility pointing to a direct effect on cell synthesis of duction of extracellular matrix (ECM) [4–6]. This is a
specific collagens. central point, since Ang II has been implicated in the
Methods. We studied the molecular mechanism for activa- pathogenesis of experimental fibrosis in the kidney. Onetion of type III collagen synthesis by Ang II in an in vitro cell
possibility is that Ang II triggers a partially characterizedmodel of myofibroblasts by evaluating (1) a1(III) collagen
series of events that begins with proteinuria and eventu-mRNA expression; (2) a1(III) collagen promoter activity; (3)
DNA/protein binding with characterization of binding sites; ally leads to the accumulation of ECM at the tubulointer-
(4) expression of transcription factors; and (5) the role of a stitial level [7]. Renal fibrosis can also be induced by
short DNA segment as Ang II responsive element.
infusion of Ang II in rats [8, 9], or it is the pathologicalResults. We found a specific dose-dependent stimulation of
substrate in those conditions such as obstructive uropa-a1(III) collagen mRNA expression and a parallel effect on
a1(III) collagen promoter activity. Transfection of constructs thies, which are characterized by high tissue levels of
containing a1(III) collagen promoter fragments of different Ang II in spite of a low level of proteinuria [10, 11]. Ang
lengths localized the site of activation within the shortest 178 II is also considered to be responsible for myocardial
bp construct. By gel-retardation experiments, we observed the
fibrosis and heart failure following an ischemic insultformation of a DNA-protein complex with crude extracts from
and/or infectious myocarditis [12–14]. The cellular ef-Ang II-stimulated cells and an oligonucleotide spanning the 3
to 20 sequence. This complex was due to a sequence-specific fects of Ang II on ECM expression, together with the
interaction and was abolished by a 3 bp substitution mutation. fibrogenic potential of the peptide in conditions that do
The introduction of this mutation into the 178 bp construct not affect renal hemodynamics, support a direct roleabolished the stimulatory effect of Ang II.
of Ang II in modulating organ fibrosis. This also is ofConclusions. These results demonstrate that Ang II stimu-
particular interest in consideration of those clinical stud-lates the expression of a1(III) collagen mRNA in myofi-
broblasts in vitro by activating the a1(III) collagen promoter ies that demonstrated the protective potential against
at the level of a factor recognition site localized immediately fibrosis and organ failure when Ang II is blocked, at
downstream of the transcription start site. This mechanism least in the kidney and the heart, an effect that occurscould be involved in Ang II-induced renal and heart fibrosis.
independently from any hemodynamic changes [12, 15,
16]. With respect to the kidney, clear evidence is avail-
able showing a prominent effect of angiotensin-con-Angiotensin II (Ang II) is a vasoactive peptide that
verting enzyme (ACE) inhibitors in protecting againstregulates the hemodynamics in organs such as the kidney
progression toward renal failure in several proteinuric
[7, 17, 18] and nonproteinuric states [7, 15, 16, 19, 20].
With reference to the heart, a few studies have shownKey words: transcription factors, renal fibrosis, heart fibrosis, extracel-
lular matrix, myofibroblasts, proteinuria. that ACE inhibitors reduce the accumulation of collagen
III in myocardium, which is the cause of altered myocar-Received for publication August 24, 1999
dium compliance in heart fibrosis [12, 21]. Also, in thisand in revised form January 7, 2000
Accepted for publication March 10, 2000 case, ACE inhibitors play their protective effect unre-
lated to changes in hemodynamics, since other antihyper-Ó 2000 by the International Society of Nephrology
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tensive drugs such as hydralazine and methyl-dopa have hours. The specificity of Ang II activity was tested by
selective competition of the peptide with saralasin. Inno effect or actually increase the collagen content of the
heart [12]. The final proof for a role of Ang II in renal this case, an increasing amount of saralasin (from 1 to
10 mmol/L) was preincubated with cells for one hour atfibrosis derives from a recent article by Fern et al in
angiotensinogen knockout mice [22]. In this model, at 378C, and then a constant amount of Ang II (0.5 mmol/L)
was added to the mixture. In a separate experiment,least 50% of the renal fibrotic response to mechanic
obstruction caused by ureteric ligation is mediated by an anti-transforming growth factor-b (TGF-b) antibody
(Roche, Zurich, Switzerland) was included in the me-Ang II, unrelated to any systemic hemodynamic change.
All of these points raise the question of how Ang II dium together with Ang II.
stimulates the synthesis of interstitial collagens in de-
Cell labeling and analysis of proteinsputed cells such as myocardial and renal myofibroblasts.
In the present work, we have directly addressed this Cells at confluence were utilized for experiments on
protein expression by including [3H]-proline in freshissue by investigating the effect of Ang II on a1(III)
collagen (COL3A1) mRNA expression and promoter standard medium. The amount of collagen synthesized
by cells was evaluated as incorporation of [3H]-prolineactivity, and we show a DNA-binding site for an Ang
II-induced factor on the COL3A1 promoter. This may in partial pepsin digests, and the collagen composition
of ECM was assayed, after pepsin digestion, by SDS-contribute to the understanding of the fibrogenic role of
Ang II, unrelated to its basic and originally recognized PAGE in nonreducing conditions, followed by autoradi-
ography. Standard collagens were labeled with [14C]-function on vasculature.
formaldehyde as described [25].
METHODS mRNA
Cell culture and characterization The expression of COL3A1 mRNA was determined
by semiquantitative reverse transcription-polymeraseH9c2(2-1) rat heart myofibroblasts were obtained
from the American Type Culture Collection (CRL1446; chain reaction (RT-PCR). Total RNA was extracted in
6 mol/L guanine-isothiocyanate. The following primerRockville, MD, USA) and were grown under a humidi-
fied atmosphere of 5% CO2 in Dulbecco’s modified Ea- pairs were used: 59 CTG GAC CAA AAG GTG ATG
CTG 39 (sense), 59 TGC CAG GGA ATC CTC GATgle’s medium (DMEM) supplemented with 10% fetal calf
serum, 1% nonessential amino acids, 1% glutamine, 100 GTC 39 (antisense) for the COL3A1 gene; 59 TGA AGG
TCG GAG TCA ACG GAT TTG GT 39 (sense) andU/mL penicillin, and 100 mg/mL streptomycin. NRK49F,
rat kidney fibroblasts, NRK52E, rat kidney tubular epi- 59 CAT GTG GGC CAT GAG GTC CAC CAC 39
(antisense) for the glyceraldehyde-3-phosphate dehy-thelial cells, CV1, and monkey kidney fibroblasts all ob-
tained by the American Type Culture Collection, were drogenase (G3PDH) gene; and 59 GGC AAG GGC
ATC CTG GCT GCA GA 39 (sense) and 59 TAA CGGalso used in some experiments.
Cells at confluence were characterized for (1) reactiv- GCC AGA ACA TTG GCA TT 39 (antisense) for the
aldolase gene. Values of COL3A1 mRNA were normal-ity to monoclonal anticytokeratin 1 to 8 antibodies (Boeh-
ringer Biochemia, Mannheim, Germany) and antifibro- ized for either G3PDH or aldolase mRNAs and were
expressed as the fold increase at various times after Angblast monoclonal antibody MAS-16b (Serotec, Leicester,
UK); (2) expression of a-smooth muscular actin (a-SMA) II cell treatment versus control untreated cells.
COL3A1 mRNA stability was assayed by Actinomy-[23] and g-myosin; and (3) production of collagen as
[3H]-proline incorporation in partial pepsin digests and cin D as previously described [26]. Briefly, cells after
incubation with 0.5 mmol/L Ang II for 30 minutes weresodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) (discussed later in this article). For treated with actinomycin D for several times from 60
minutes to 24 hours. COL3A1 mRNA was evaluated bya-SMA, isoelectric focusing in a narrow range of carrier
ampholytes (Amersham Pharmacia, Biotech Milan, Italy) RT-PCR (discussed previously in this article).
was performed on cellular extracts followed by immu-
COL3A1 plasmid constructionsnoblotting with a monoclonal antibody against a-SMA
(Dako, Milan, Italy). For g-myosin, gradient SDS-PAGE Polymerase chain reaction amplification from human
genomic DNA was used to amplify fragments of theaccording to Laemmli was performed on cellular extracts
followed by immunoblotting with a monoclonal antibody COL3A1 59 flanking region [27]. A 1436 bp fragment
from 21375 to 161 relative to the transcription start siteagainst g-myosin (Roche, Zurich, Switzerland) [24].
When required, cells were incubated in the absence was obtained using a pair of primers: sense 59 GAT CAA
GCT TGC AAG TTT GCC ACT GTC CAT G 39 andor in the presence of Ang II (0.1 to 1.0 mmol/L) without
serum. Incubation was performed in DMEM at 378C antisense 59 CTC AAG CTT AGC ACC ATC AAG
TTG TTC CC 39, both carrying a HindIII restriction siteunder 5% CO2 for various times, from 10 minutes to 48
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Fig. 1. The a1(III) collagen (COL3A1) pro-
moter constructs utilized in this study. (A) The
three constructs, pRup4, pRup6, pFV1, with
the indicated promoter length. (B) The se-
quence of COL3A1 promoter between 2117
to 161 (pFV1). (C) The sequence of oligo-
nucleotides 414 (wild-type sequence), and
mutated 414m, 414m1, and 414m2 (the base
substitutions introduced in mutant oligonucle-
otides are indicated in bold and underlined).
at their 59 end. A 318 bp fragment (2257 to 161) was DNA transfections
obtained with a sense primer 59 GCG AAG CTT CTA Transfections were performed in cells maintained in
TAC GTT CCT 39, also carrying the HindIII restriction DMEM medium supplemented with 10% fetal calf se-
site, and the same antisense primer that was mentioned rum, 100 mU/mL penicillin, and 100 mg/mL streptomycin
previously in this article. The amplified fragments were in a humidified atmosphere of 5% CO2. The cells were
inserted into the pGL2-basic vector (Promega, Inc., plated approximately 18 hours before transfection at a
Madison, WI, USA) upstream of the luciferase reporter density of 0.75 3 106 cells in 10 cm diameter plastic dishes.
gene, after digestion with HindIII, giving rise to the Transfections were performed using 5 mg of total plasmid
pRup4 (1436 bp insert) and the pRup6 (318 bp insert) DNA with 100 mmol/L polyethylenimine (Sigma-Aldrich,
constructs. The pFV1 (2117 to 161) construct was ob- St. Louis, MO, USA). The size of different plasmid con-
tained from pRup6 after digestion with SspI and removal structs was always considered by using equimolar
of the sequence in excess. All constructs were controlled amounts of the different constructs and bringing the final
by DNA sequencing. Figure 1 describes the plasmid con- amount to 5 mg by adding pBluescript (Stratagene, La
Jolla, CA, USA) plasmid DNA. Plasmid pRL-Renillastructs.
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Luciferase (0.4 mg; Promega) was always cotransfected competitor oligonucleotide. For supershift assays, spe-
cific antibodies were included in the preincubation mix-as an internal standard. Twenty-four hours after the addi-
tion of DNA, cells were washed twice with phosphate- ture prior to the addition of the probe and loading onto
polyacrylamide gels, and a lane containing preimmunebuffered saline (PBS), re-fed with serum-free fresh me-
dium with or without Ang II, and further incubated for serum was always included as control.
the desired period (from 10 minutes to 48 hours). Trans-
Mutagenesisfection efficiency was evaluated by determining expres-
sion of a SV40-renilla luciferase vector (Dual Luciferase Plasmid pFV1M was made by site-directed mutagene-
sis using a two-step procedure based on PCR [30] toReport Assay System; Promega). All transfections were
repeated in quintuplicate in at least three independent introduce substitutions into the original FV1 plasmid.
experiments. Results are expressed as mean 6 SEM.
Western blot analysis
Preparation of cellular and nuclear extracts Cellular extracts were subjected to SDS-PAGE (8 to
16% polyacrylamide) and Western blot analysis accordingTotal extracts from both controls and cells incubated
with 0.5 mmol/L Ang II for various times were prepared to Beisiegel [31]. Chemiluminescent detection was car-
ried out according to the manufacturer’s specificationsby lysis with RIPA buffer (1 3 PBS, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 0.5 mmol/L phenyl- (ECL Super-signal, Ultra; Pierce, Rockford, IL, USA),
using peroxidase-conjugated antirabbit IgG (1:10,000).methylsulfonyl fluoride). After 30 minutes at 48C, the
mixture was centrifuged at 14,000 r.p.m. for 15 minutes, Antibodies recognizing several transcription factors [Stat
1 and 3, p65, p50 and c-Rel subunits of nuclear factor-kBand the supernatant was treated as a whole cell extract
for Western blot. (NF-kB), c-Fos, c-Jun, AP2, C/EBPb, Myo-D, myogenin,
Myf-5, MEF-2, and SP1] were used at 1:1000 to 10,000Nuclear extracts, from control cells or cells incubated
with Ang II, were prepared as previously described [28] dilution. All antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).with a slight modification of the buffer (buffer A) used
for resuspending cells scraped from culture plates, as
follows: 20 mmol/L HEPES, pH 7.9, 1 mmol/L ethylene-
RESULTS
diaminetetraacetic acid (EDTA), 1 mmol/L dithiothreitol,
Cell characterization0.5 mmol/L phenylmethylsulfonyl fluoride, and 1 mg/mL
each of leupeptin, aprotinin, and pepstatin. H9c2(2-1) rat heart cells have been characterized for
markers that are typical of fibroblast/myofibroblast cells,
Gel retardation assay to clarify whether this cell line can be considered a model
of myofibroblasts, the cell type that is present in tissuesFor DNA-binding assay, double-stranded oligonucleo-
tides corresponding to various elements in the COL3A1- progressing toward fibrosis. H9c2(2-1) showed an elon-
gated morphology as fibroblasts, strongly positive expres-promoter were used as [32P]-labeled probes or as unla-
beled competitors. Following, the sequences of wild-type sion of a-SMA and g-myosin, and negative staining for
the antifibroblast MAS-16 antibody, whereas NRK49Fand mutant double-stranded oligonucleotides are re-
ported (Fig. 1): 414 (from 3 to 20 in COL3A1 promoter; and CV1 kidney fibroblasts were negative for a-SMA
and g-myosin and positive for MAS-16 reactivity (Fig. 2;upper strand 59-TGG CTG AGT TTT ATG ACG-39),
414m (upper strand 59-TGG CGT CAG CGT ATG data not shown). Finally, production of type III and
type I collagen chains was strongly positive in H9c2(2-1)ACG-39); 414 m1 (upper strand 59-TGG CGT CAT TTT
ATG ACG-39), and 414m2 (upper strand 59-TGG CTG (discussed in the following section; Fig. 3). According to
these results, we conclude that this cell line is in fact aAGG CGT ATG ACG-39) in which the substituted bases
are in bold. The assays were performed essentially as myofibroblast cell.
previously described [29]: nuclear extracts (5 mg protein),
Stimulation of collagen expression by Ang IIfrom both control and Ang II-treated cells, were incu-
bated with 10 fmol of labeled oligonucleotide (around To determine the effect of treatment with Ang II on
collagen expression in myofibroblasts, quiescent cells15,000 cpm) in a total volume of 15 mL containing 20
mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaCl, 0.35 were treated with increasing amounts of Ang II from
0.1 to 1.0 mmol/L for 24 hours. Figure 3B shows that 0.5mmol/L dithiothreitol, 0.5 mmol/L phenylmethylsulfonyl
fluoride, 10% glycerol, and 1 mg of poly (dI-dC). The mmol/L Ang II significantly increased the [3H]-proline
incorporation into collagens by 100%. In parallel, Angbound complexes were separated from the free probe by
electrophoresis on 5% polyacrylamide gels. Complexes II did not modify the composition of collagens produced
by these cells, mostly a1(I), a2(I), and a1(III)3 (Fig.were visualized by autoradiography of the dried gels.
Competition experiments were performed in the pres- 3A), which indicates that Ang II induced a twofold net
increase of synthesis of both these collagens. Based onence of a 100- to 400-fold molar excess of unlabeled
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Fig. 2. Expression of a-smooth muscle actin (a-SMA) and g-myosin in different cell lines. The H9c2(2-1) fibroblast cell line derived from rat
heart, NRK49F, and CV1 fibroblasts derived from rat and monkey kidney, respectively, were analyzed as indicated.
Fig. 3. Collagen synthesis and composition by H9c2(2-1) cells. (A) The a1(III) trimer and a1(I) and a2(I) chains are indicated in samples from
0.5 mmol/L Ang II-treated ( ) and -untreated ( ) cells, normalized for same amount of [3H] radioactivity. (B) Total [3H]-proline incorporation
in H9c2(2-1) and NRK52E-treated and -untreated cells.
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Fig. 5. Time- and dose-response curves of Ang II stimulation of
COL3A1 promoter activity. Percent increase of COL3A1 promoter-
luciferase fusion gene expression after transfection in Ang II-treated
cells versus -untreated transfected cells, related to time of incubation
with Ang II (A) or Ang II concentration in cell culture medium (B).
Symbols are: (m) pFV1 construct; (d) pRup6 construct. Values repre-
Fig. 4. COL3A1 mRNA accumulation and decay in H9c2(2-1) cells. sent mean of luciferase assays, normalized for SV40-renilla luciferase
(A) Expression of COL3A1 mRNA was evaluated by RT-PCR, and expression, performed in duplicate.
the results are reported as percentage increase of mRNA level in
Ang II (0.5 mmol/L)-treated versus -untreated cells, normalized by
expression of two different housekeeping genes, glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) and aldolase. Symbols are: (d)
An analysis of mRNA stability performed on Ang II-COL3A1/aldolase; (h) COL3A1/G3PDH. (B) Decay curve of COL3A1
mRNA, evaluated by RT-PCR, after actinomycin D incubation of Ang treated and -untreated cells, after blocking actinomycin
II-treated (0.5 mmol/L; d) and -untreated (h) cells.
D mRNA synthesis, showed a more rapid decay of mRNA
from treated cells (Fig. 4B), suggesting that although at
a limited extent, a post-transcriptional regulation also
these data and on the composition of fibrotic tissues in
contributes to the overall COL3A1 mRNA accumula-
humans, in which accumulation of type III interstitial
tion. This implies that the higher stimulation of COL3A1collagen is particularly evident, further experiments on
mRNA by Ang II is, to some extent, counterbalanced
a1(III)3 regulation were performed. by a faster decay and determines the final level of type
III collagen resulting from Ang II treatment (Fig. 3).Stimulation by Ang II of COL3A1 mRNA
We first determined the levels of COL3A1 mRNA
Effect of Ang II on COL3A1 promoter activityafter induction of myofibroblasts with 0.5 mmol/L Ang
To evaluate the effect of Ang II at the level of COL3A1II for increasing time periods. Semiquantitative RT-PCR
promoter, a time-course experiment was performed byanalysis showed a peak of increment of COL3A1 accu-
transfecting H9c2(2-1) rat heart myofibroblasts withmulation by 400% compared with unstimulated cells at
pRUP6 and pFV1 constructs using 0.5 mmol/L Ang II30 minutes, with a subsequent decrease up to a stable
50 to 100% higher level in treated cells (Fig. 4A). for increasing time intervals. Figure 5A shows a maximal
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Fig. 7. Response to Ang II treatment of different COL3A1 promoterFig. 6. Block of Ang II-induced COL3A1 promoter stimulation by constructs. pRup 4, pRup6, pFV1 wild-type and pFV1M (mutant)saralasin. Symbols are: ( ) effect of preincubation with saralasin at constructs were transfected in H9c2(2-1) cells either incubated or not
the indicated concentrations on Ang II stimulation (h); (j) effect of incubated with 0.5 mmol/L Ang II for 30 minutes. The bars show
anti–TGF-b antibody. percentage increase of promoter activity in treated versus untreated
cells 6 SEM in three different experiments performed in quintuplicate.
stimulatory effect at 30 minutes. In Figure 5B, a dose–
response curve shows maximal stimulation at 0.5 mmol/L structs, incubated with the same Ang II concentrations
and for an identical time period, were stimulated to aAng II concentration. Figure 6 demonstrates that the
induced increase of promoter activity was specifically lower extent (50% pRUP4 and 100% pRUP6, respec-
tively), suggesting that a maximal response was obtaineddependent on Ang II treatment. Cells transfected with
pRUP6 and stimulated with Ang II had a 100% increase after removal of parts of the promoter sequence likely
to contain inhibitory elements.in promoter activity with respect to untreated cells, while
saralasin, which competes with Ang II at the receptor
Factor-binding site within the responsive regionlevel, abolished, in a dose-dependent manner, the stimu-
latory effect of Ang II. Another attempt to block the Based on the results mentioned previously in this arti-
cle, the cis-acting elements responsive to Ang II appearactivity of pRup6 was done with specific antibodies
against TGF-b (Fig. 6), but in this case, no inhibitory to be localized within a 178 bp fragment of COL3A1
promoter contained in the pFV1 construct. To identifyeffect was observed, suggesting no relationship between
TGF-b and stimulation by Ang II in our transfection the trans-acting factor(s) that mediate the Ang II pro-
moter stimulation, different oligonucleotides that repro-assay, which utilizes the 318 bp promoter insert.
duced candidate sequences were synthesized for binding
Localization of cis-acting Ang II responsive elements of known transcription factors. One of these, oligonucle-
in COL3 A1 promoter otide 414 (Fig. 1C), demonstrated binding with factors
contained in nuclear extracts stimulated with Ang II andTo localize the responsive elements inside the COL3A1
promoter more precisely, constructs containing different absent in nuclear extracts from control cells. In fact, as
shown in Figure 8, no binding with labeled 414 oligonu-promoter fragments were assayed in transient transfec-
tion experiments in the same cells (Fig. 7). When com- cleotide was observed with nuclear extracts of control
cells (lane 1), while the extracts of cells stimulated withparing promoter activity of pRUP4, pRUP6, and pFV1
in untreated myofibroblasts, we found equivalent values Ang II produced the formation of retarded complexes
with the radiolabeled oligo (Fig. 8, lanes 2 through 15).for pRUP4 and pRUP6 and a 50% increased activity for
pFV1. Ang II was most effective on promoter activity Two differently moving complexes were observed, both
of which were competed by an excess of the same unla-of the shortest pFV1 construct (178 bp), with a fivefold
increase compared with control cells. The other con- beled 414 oligonucleotide (Fig. 8, lanes 3 through 5).
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Fig. 8. Binding of nuclear proteins to a pro-
moter sequence between 13 and 120. The
414 oligonucleotide, which reproduces the 13
to 120 sequence, was used in EMSA assay
as a labeled probe (lanes 1 through 15) with
nuclear extract from untreated cells (lane 1)
or from Ang II-treated cells (lanes 2 through
15), and as unlabeled competitor at increasing
concentration (lanes 3 through 5). Mutant 414
oligonucleotides, 414m with a 7 bp substitu-
tion (lanes 6 through 8), 414m1 with a 4 bp
substitution (lanes 9 through 11), and 414m2
with a 3 bp substitution (lanes 12 through 14)
were also used as competitors. The labeled
414m oligonucleotide was used as probe in
lane 16.
Based on the possibility that oligonucleotide 414 con- To obtain further information about the DNA-binding
factors recognizing the 414 oligonucleotide, nuclear ex-tained a recognition site for the Ang II factor, we synthe-
tracts were subjected to partial purification by ammo-sized a mutated oligonucleotide with a 7 bp substitution
nium sulfate differential precipitation. Figure 9A showsin the putative binding site, 414m (Fig. 1C), which when
that two different factors could be separated by thistested as a competitor showed no competition ability
mean at 40 and at 60% ammonium sulfate saturation,(Fig. 8, lanes 6 through 8), nor was it able to form any
respectively, and after separation, both were able to bindretarded complex when was used as a labeled probe
the same probe, suggesting that these two factors were(Fig. 8, lane 16 compared with lane 15). To further local-
bound independently on each other. The retarded com-ize the factor-binding site inside this 7 bp sequence, two
plexes observed by using the two fractions obtained wereadditional mutated oligonucleotides, 414m1 with a 4 bp
specifically competed by the unlabeled wild-type oligo-substitution and 414m2 with a 3 bp substitution (Fig.
nucleotide and not by the mutant, confirming specific1C), were also used in competition assays showing that
binding properties (Fig. 9B).while some competition was observed with the 414m1
oligonucleotide, no competition was observed with the Effect of promoter mutagenesis on response to Ang II
414m2 oligonucleotide, suggesting that the three substi- To evaluate the functional role of the factor binding
tuted nucleotides (TTT inside the binding sequence) are site inside the 414 oligonucleotide, we introduced the
essential. same 3 bp substitution that abolished the binding of
The hypothesis that the 7 bp sequence contained in the two factors into the pFV1 construct, by site-specific
oligonucleotide 414 could be an AP1 recognition site mutagenesis. Transfection of the two wild-type and mu-
was tested by including specific anti-c Jun and c-Fos tant pFV1 plasmids in myofibroblasts demonstrated that
antibodies in the assay, but we were unable to show any the mutated construct did not respond to Ang II stimula-
effect either of supershift or abolition of the observed tion (Fig. 6).
retarded complex (data not shown). Other antibodies
Transcription factors expression in cell extractsraised against Stat 1 and 3, p65, p50, and c-Rel subunits
of NF-kB, AP2, C/EBPb, Myo-D, myogenin, Myf-5, In the attempt to identify transcription factors that
might interact with the cis-acting element inside theMEF-2, and SP1 were also tested, with no effect.
Ghiggeri et al: A DNA element responsive to Ang II 545
Fig. 9. Partial purification of nuclear extracts from Ang II-treated H9c2(2-1) cells by ammonium sulfate differential precipitation. Nuclear extract
from untreated cells (2) or from Ang II-treated cells (1), either unpurified or partially purified at the indicated ammonium sulfate concentration
were used in EMSA assay with the 414 oligonucleotide-labeled probe in the presence or in the absence of wild-type or mutated competitor
oligonucleotide.
pFV1 construct or that are modulated by Ang II cell dominant idea, Ang II would stimulate fibrogenesis at
the tubulointerstitial level by altering the glomerular he-treatment [32], we performed Western blot analysis on
modynamics and eventually by inducing proteinuria [7].extracts from Ang II-stimulated myofibroblasts in the
Proteinuria would, in turn, stimulate osteopontin [9] andsame conditions as the experiments mentioned pre-
other chemoattractants, and trigger the inflammatoryviously in this article, utilizing a panel of antibodies
cascade. However, this hypothesis does not explain theraised against transcription factors. A significant and
effects of Ang II in conditions, such as obstructive ne-rapid induction (30 to 60 minutes) of the Stat 1 factor was
phropathy, which are not proteinuric [15] and only par-observed, while the Stat 3 factor showed a progressive
tially affect renal hemodynamics. In accordance, miceincrease up to six hours. The NF-kB p50 subunit showed
knocked out for angiotensinogen have an attenuateda peak of stimulation at two hours, whereas the p65
fibrotic response to ureteral ligation independent of sys-subunit showed a less pronounced pattern of increase,
temic hemodynamic changes [22]. At the same time,with maximum expression at two hours (data not shown).
ACE inhibitors counteract the progression of experi-
mental chronic tubulointerstitial nephropathy [16], an-
DISCUSSION other condition in which evident proteinuria is absent.
Several lines of evidence indicate that Ang II plays a Moreover, ACE inhibitors attenuate fibrosis in the heart,
pathogenic role in fibrosis of several organs, particularly while other antihypertensive drugs, which induce a com-
the kidney and the heart, which is considered a secondary parable hemodynamic effect [12], do not. Based on these
event following acute inflammatory and/or ischemic in- observations, we followed the hypothesis that Ang II
sults. exerts a fibrogenic effect unrelated to the mechanism
At least in the kidney, this effect has been related to implicating hemodynamic problems, which is supported
by the observation that Ang II directly stimulates thethe vasoactive functions of the peptide. According to the
Ghiggeri et al: A DNA element responsive to Ang II546
production of ECM in cellular models such as in mesan- mesangial cell model [4]. We previously reported that
TGF-b–responsive elements are located upstream ofgium [4, 5] and cardiac myofibroblasts.
Kidney tubulointerstitial fibrosis, as well as heart fi- pRup6 in the COL3A1 promoter [45], but the longest
pRup4 construct containing these elements showed abrosis, is characterized by the accumulation of interstitial
collagens, mainly type III collagen [33–35], in which the substantially comparable response to Ang II as pRup6,
thus implying no major role of TGF-b in Ang II promoterproduction is due to the presence of cells of mesodermal
origin. Tissue culture experiments showed that two renal stimulation.
Transfection experiments with deleted promoter con-cell types, fibroblasts and tubular epithelial cells, are both
able to synthesize ECM components in vitro [36]. How- structs restricted the target of Ang II activity in a pro-
moter sequence included in the pFV1 construct and pro-ever, another cell type, myofibroblasts, has been impli-
cated in pathological production of ECM [37, 38]. These tein/DNA binding experiments localized a specific 7 bp
cis-acting element immediately downstream of the tran-cells are not physiologic components of the heart and of
the kidney; they are differentiated cells with morphologic scription start site of the gene. Several experiments sup-
ported this conclusion. First, the oligonucleotide con-features intermediate between those of fibroblasts and
smooth muscle cells [39, 40]. In vitro experiments showed taining this element formed a complex with crude nuclear
extracts from cells stimulated by Ang II, which was notthat renal fibroblasts are able to differentiate to myofi-
broblasts [41]. In the kidney, the presence of myofi- detected with extracts from nonstimulated cells. Muta-
tion at the site of the oligonucleotide sequence abolishedbroblasts in the tubulointerstitium correlates with inter-
stitial fibrosis and the worsening of renal function in the formation of the DNA-protein complex, while com-
petition of the oligonucleotide probe with excess of theseveral renal pathologies such as IgA nephropathy [42],
chronic pyelonephrites [43], and chronic rejection [44]. same unlabeled oligonucleotide inhibited the complex
formation. Finally, when the same point mutation wasMost interestingly, in different studies utilizing double
immunostaining for a-SMA, which is a marker for myo- introduced in the original construct of COL3A1 pro-
moter, the effect of Ang II was abolished. Altogether,fibroblasts, and type III collagen, it has been shown that
this collagen derives only from myofibroblasts [37, 38]. these results underscore the importance of activation of
transcription in COL3A1 expression stimulation, whichSince myofibroblasts, either in tubulointerstitial domains
or in myocardium, are considered the cells playing a is even more striking if we consider that a more rapid
decay of COL3A1 mRNA in Ang II-stimulated cellsmajor role in progression toward fibrosis [37–44], we
tested the possibility that they might be targets of a direct would suggest that a post-transcriptional mechanism
contributes to some extent to the final level of mRNAeffect of Ang II on the synthesis of type III collagen.
In this work, we utilized a cellular model, the H9c2(2-1) accumulation.
Detection of a specific protein/DNA complex in nu-cell line, derived from rat heart that fitted the characteris-
tics of myofibroblasts with respect to: (1) morphology clear extracts from Ang II-treated cells and the role
of the target cis-acting element prompted us to bettersimilar to fibroblasts; (2) positivity for a-SMA and g-myo-
sin; and (3) production of interstitial collagens such as characterize the trans-acting factor that mediates the ob-
served functional effect of Ang II. It is noteworthy thattype I, type III, and type V, which accumulate in fibrotic
tissues and are not, by definition, produced by myoblasts. the sequence of the cis-acting regulatory element is
highly conserved in several species, from chicken to hu-Our experimental approach was to determine possible
regulatory effects of Ang II on COL3A1 mRNA expres- mans, which indicates a fundamental role in gene regula-
tion. The analysis of this sequence suggested the pres-sion, the gene coding for one of the most important
fibrogenic collagens in humans. In our cellular system, ence of potential binding sites for already characterized
transcription factors; however, inclusion of antibodies inAng II stimulated both COL3A1 mRNA and protein
expression, which prompted us to define the level at gel retardation assays did not give positive results. On
the other hand, the expression of some of these factorswhich up-regulation of type III collagen by Ang II is
determined. We evaluated the effect of Ang II on detected by Western blot of cellular extracts from Ang
II treated cells showed up-regulation of Stat 1 and 3COL3A1 promoter and observed a rapid stimulation of
the promoter activity, which was specific since it was and the NF-kB p50 subunit, which might be indirectly
involved in an Ang II-activated pathway, which is yetprevented by treatment with saralasin, an Ang II recep-
tor antagonist. Moreover, anti–TGF-b antibodies in the poorly understood.
In an attempt to characterize the trans-acting factorcell culture medium did not modify the stimulatory effect
of Ang II, this experiment being confined to the construct stimulated by Ang II, an initial biochemical analysis has
shown the presence of two independent components,utilized here (pRUP6), which has a promoter insert of
318 bp. Therefore, the present results showed that the both able to bind specifically the target sequence. A
further analysis is presently in process.stimulatory effect of Ang II in this region is not due to
an autocrine loop involving TGF-b, as described in the In conclusion, we describe a stimulatory activity of
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associated with chronic aminonucleoside nephrosis: AmeliorationAng II on COL3A1 promoter and COL3A1 mRNA that
by angiotensin I converting enzyme inhibition. Am J Pathol
is dependent on the binding of a trans-acting factor to 137:1323–1332, 1990
a cis-acting element localized just downstream of the 16. Uemasu J, Fujiwara M, Munemura C, Kawasaki H: Long-term
effects of enalapril in rat with experimental chronic tubulo-intersti-transcription start site. This mechanism of COL3A1 acti-
tial nephropathy. Am J Nephrol 13:35–42, 1993vation could be involved in the pathogenesis of heart 17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of
and renal tubulointerstitial fibrosis. angiotensin-converting-enzyme inhibition on diabetic nephropa-
thy: The Collaborative Study Group. N Engl J Med 329:1456–1462,
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